SynthesisESC heart failure2025
T1 mapping and major cardiovascular events in non-ischaemic dilated cardiomyopathy: a systematic review and meta-analysis.
Synthesis in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- T1 mapping and major cardiovascular events in non-ischaemic dilated cardiomyopathy: a systematic review and meta-analysis.ESC heart failure · 2025Pooled it
- Assessment of myocardial fibrosis in ischemic and non-ischemic cardiomyopathies using cardiac magnetic resoance non-contrast T1ρ mapping.Frontiers in cardiovascular medicine · 2026Article
- Cardiovascular imaging in 2024: review of current research and innovations.European heart journal. Imaging methods and practice · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of this study is to investigate the prognostic role of T1 mapping techniques in predicting major adverse cardiovascular events (MACE) in patients affected by non-ischaemic dilated cardiomyopathy (NIDCM) by performing a meta-analysis of available studies. METHODS AND
resultsData from 12 observational studies exploring the prognostic role of native T1 mapping and extracellular volume (ECV) were analysed with random effect generic inverse variance. The primary endpoint was MACE defined as a composite of heart failure or arrhythmic-related events, expressed as hazard ratio (HR) with 95% confidence interval (CI). Secondary main outcomes were heart failure-related events, arrhythmic-related events, and weighted mean difference of native T1 mapping values or ECVs between patients with or without MACE. Overall, 4025 patients with NIDCM were included. The median follow-up length was 22 (IQR 14-22) months. The primary outcome of MACE occurred in 610 patients with a pooled HR for native T1 mapping values of 1.07 (95% CI 1.04-1.09, I
conclusionsIn NIDCM patients, native T1 mapping and ECV were associated with increased risk of the composite primary endpoint of MACE and the secondary endpoint of heart failure and arrhythmic-related events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.